Cancer
Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers an...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Livre numérique |
| Lingua: | Anglais |
| Pubblicazione: |
Berlin, Heidelberg :
Springer Berlin Heidelberg
[20..].
Cham : Springer Nature |
| Edizione: | 1st ed. 2007. |
| Serie: | Topics in Medicinal Chemistry
1 |
| Accesso online: | Accès sur la plateforme de l'éditeur Accès sur la plateforme Istex Accès Université d'Orléans Accès INSA CVL |
| Nota: |
Archives Springer e-books (Licence nationale) Archives Springer e-books (Licence nationale) |
| Autres localisations: | Voir dans le Sudoc |
| Variante du titre: | With contributions by numerous experts |
| Edition sous un autre format: | • Cancer, Texte imprimé, 9783540331193 • Cancer, Texte imprimé, 9783540822011 • Cancer, Texte imprimé, 9783642069666 • Cancer, Texte imprimé, 9783540331193 |
| Riassunto: | Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers and its potential biological effects (e. g. , competitive growth advantage, evasion from apoptosis and therapy resistance) has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents. Following this strategy, a number of compounds have demonstrated antitumor activity in preclinical and clinical settings by targeting directly or indirectly the different components of this pathway. This work covers - cent salient medicinal chemistry achievements in the identi?cation of these pathway modulators, updating recent reports on this class of potential c- cer drugs [1 4]. To help the reader, each section of this piece of work starts with a brief background to understand the target rationale and then moves on to the lead discovery, drug optimization, and clinical results stages as - propriate. A schematic representation of signaling through this pathway and the pathway components covered herein are shown in Fig. 1. Fig. 1 Schematic representation of signaling through the PI3K/PKB pathway 172 C. Garcia-Echeverria 2 Insulin-likeGrowthFactorI Receptor The Insulin-like Growth Factor-I Receptor (IGF-IR) is a member of the - sulin receptor family of tyrosinekinases. This transmembrane-spanning p- tein is composed of two ?-andtwo ?-subunits linked by disul?de bonds |
|---|---|
| Descrizione del documento: | Archives Springer e-books (Licence nationale) Archives Springer e-books (Licence nationale) |
| ISBN: | 9783540331209 |
| ISSN: | 1862-247X |
| Accesso: | Accès en ligne pour les établissements français bénéficiaires des licences nationales Accès soumis à abonnement pour tout autre établissement Conditions particulières de réutilisation pour les bénéficiaires des licences nationales. https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 |